duloxetine sandoz 30 mg gastro - resistant capsules, hard
30 mg gastro - resistant capsules, hard
duloxetine sandoz 60 mg gastro - resistant capsules, hard
60 mg gastro - resistant capsules, hard
omeprazole sandoz 20 mg gastro - resistant capsules, hard
20 mg gastro - resistant capsules, hard
clopidogrel sandoz
acino pharma gmbh - клопидогрел - peripheral vascular diseases; stroke; myocardial infarction - Антитромботични агенти - Клопидогрел е показан при възрастни за предпазване от атеротромботични инциденти при: * пациенти, страдащи от миокарден инфаркт (от няколко дни до 35 дни), исхемичен инсулт (от 7 дни до по-малко от 6 месеца) или установено периферно артериална болест. За повече информация, моля, вижте раздел 5.
dupixent
sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - Средства за дерматит, с изключение на кортикостероиди - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.
scandonest 2% special with adrenaline 1 : 100 000 solution for injection
septodont. - mepivacaine, комбинации - 1 : 100 000 solution for injection
scandonest 30 mg/ml solution for injection
septodont. - mepivacaine - 30 mg/ml solution for injection
sandimmun neoral 100 mg/ml oral solution
novartis pharma gmbh - Циклоспорин - 100 mg/ml oral solution
sandostatin 100 microgram/1 ml solution for injection/infusion
novartis pharma gmbh - Октреотид - 100 microgram/1 ml solution for injection/infusion
sandostatin lar 20 mg powder and solvent for suspension for injection
novartis pharma gmbh - Октреотид - 20 mg powder and solvent for suspension for injection